Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
Abstract:6028 Background: Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) activation and CD8 T-cell activation. The stimulation of the dendritic cell network and subsequent T cell recruitment with efti may lead to stronger anti-tumor responses in combination than observed with pembrolizumab alone. We hereby report results of the 2nd line metastatic squamous head and neck carcinoma (HNSCC) cohort (part C) of phase II trial (NC… Show more
“…In the case of NSCLC, the relatively favorable immune environment in most NSCLC cases 653 suggests that targeting these additional checkpoints could potentially be advantageous. LAG-3 agents have demonstrated efficacy in solid tumor entities such as NSCLC and HNSCC, [52][53][54] and TIGIT agents are currently in several clinical trials in combination with PD-1/PD-L1 agents in NSCLC (Table 1). Exploration of B7 is ongoing across various solid tumors.…”
Section: Discussionmentioning
confidence: 99%
“… 52 Other combinations like miptenalimab plus ezabenlimab and favezelimab plus pembrolizumab are still under phase I exploration (Table 1 and Supplementary Table 1 ). LAG-3-Ig fusion protein eftilagimod alpha plus pembrolizumab caused an overall response rate (ORR) of 33% and 50% in pembrolizumab-refractory and anti-PD-1 naïve non-small cell lung cancer (NSCLC) patients, respectively, 53 and showed a similarly considerable effect 54 in head and neck squamous cell carcinoma (HNSCC) patients, thus was granted fast track status by FDA for NSCLC and HNSCC. The LAG-3 pathway has thus now been established as the third immune checkpoint pathway that can be inhibited to stimulate anti-tumor immune responses with clinical benefit.…”
Section: Inhibitory Checkpoints and Protein Familiesmentioning
Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance and toxicity still remain. Due to the advancement of immuno-oncology, an increasing number of novel immunoregulatory targets and mechanisms are being revealed, with relevant therapies promising to improve clinical immunotherapy in the foreseeable future. Therefore, comprehending the larger picture is important. In this review, we analyze and summarize the current landscape of preclinical and translational mechanistic research, drug development, and clinical trials that brought about next-generation pharmacological immunoregulatory anti-cancer agents and drug candidates beyond classical immune checkpoint inhibitors. Along with further clarification of cancer immunobiology and advances in antibody engineering, agents targeting additional inhibitory immune checkpoints, including LAG-3, TIM-3, TIGIT, CD47, and B7 family members are becoming an important part of cancer immunotherapy research and discovery, as are structurally and functionally optimized novel anti-PD-(L)1 and anti-CTLA-4 agents and agonists of co-stimulatory molecules of T cells. Exemplified by bispecific T cell engagers, newly emerging bi-specific and multi-specific antibodies targeting immunoregulatory molecules can provide considerable clinical benefits. Next-generation agents also include immune epigenetic drugs and cytokine-based therapeutics. Cell therapies, cancer vaccines, and oncolytic viruses are not covered in this review. This comprehensive review might aid in further development and the fastest possible clinical adoption of effective immuno-oncology modalities for the benefit of patients.
“…In the case of NSCLC, the relatively favorable immune environment in most NSCLC cases 653 suggests that targeting these additional checkpoints could potentially be advantageous. LAG-3 agents have demonstrated efficacy in solid tumor entities such as NSCLC and HNSCC, [52][53][54] and TIGIT agents are currently in several clinical trials in combination with PD-1/PD-L1 agents in NSCLC (Table 1). Exploration of B7 is ongoing across various solid tumors.…”
Section: Discussionmentioning
confidence: 99%
“… 52 Other combinations like miptenalimab plus ezabenlimab and favezelimab plus pembrolizumab are still under phase I exploration (Table 1 and Supplementary Table 1 ). LAG-3-Ig fusion protein eftilagimod alpha plus pembrolizumab caused an overall response rate (ORR) of 33% and 50% in pembrolizumab-refractory and anti-PD-1 naïve non-small cell lung cancer (NSCLC) patients, respectively, 53 and showed a similarly considerable effect 54 in head and neck squamous cell carcinoma (HNSCC) patients, thus was granted fast track status by FDA for NSCLC and HNSCC. The LAG-3 pathway has thus now been established as the third immune checkpoint pathway that can be inhibited to stimulate anti-tumor immune responses with clinical benefit.…”
Section: Inhibitory Checkpoints and Protein Familiesmentioning
Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance and toxicity still remain. Due to the advancement of immuno-oncology, an increasing number of novel immunoregulatory targets and mechanisms are being revealed, with relevant therapies promising to improve clinical immunotherapy in the foreseeable future. Therefore, comprehending the larger picture is important. In this review, we analyze and summarize the current landscape of preclinical and translational mechanistic research, drug development, and clinical trials that brought about next-generation pharmacological immunoregulatory anti-cancer agents and drug candidates beyond classical immune checkpoint inhibitors. Along with further clarification of cancer immunobiology and advances in antibody engineering, agents targeting additional inhibitory immune checkpoints, including LAG-3, TIM-3, TIGIT, CD47, and B7 family members are becoming an important part of cancer immunotherapy research and discovery, as are structurally and functionally optimized novel anti-PD-(L)1 and anti-CTLA-4 agents and agonists of co-stimulatory molecules of T cells. Exemplified by bispecific T cell engagers, newly emerging bi-specific and multi-specific antibodies targeting immunoregulatory molecules can provide considerable clinical benefits. Next-generation agents also include immune epigenetic drugs and cytokine-based therapeutics. Cell therapies, cancer vaccines, and oncolytic viruses are not covered in this review. This comprehensive review might aid in further development and the fastest possible clinical adoption of effective immuno-oncology modalities for the benefit of patients.
“…Relatlimab is a MoAb that is being investigated either in combination with nivolumab plus ipilimumab or with nivolumab plus an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor in a phase I/II study in the advanced setting (NCT03459222) (Table 5.2). Eftilagimod alpha is a soluble LAG-3 protein that binds to a subset of major histocompatibility complex (MHC) class II molecules to mediate antigen presenting cell activation and CD8 T-cell activation, that was studied in combination with pembrolizumab in a phase II trial for HNSCC patients who had progressed on or after a first-line platinum-based therapy (NCT03625323) [11]. First reported results showed an encouraging ORR of 31.4% (95% CI: 16.9-49.3%) in patients unselected for PD-L1 tumor expression and deserves further development [11] (Table 5.…”
Section: Targeting Other Immune Checkpointsmentioning
Anti-PD-1 immune checkpoint inhibitors have recently revolutionized the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) patients, both in the first and second recurrent and metastatic settings. However, not all patients respond to PD-1 blockade, nor derive prolonged benefit from these immunotherapies, requiring further development of immune-oncology strategies beyond PD-1/PD-L1 inhibitors. There has been an important therapeutic development with the evaluation of many new immune checkpoints molecules and other type of immunomodulatory molecules, along with combinations of these new agents with PD-1/PD-L1 inhibitors, but very few of these strategies have shown significant anti-tumor activity as single agent in HNSCC patients, and further results are awaited from ongoing trials. All randomized trials assessing novel immune-oncology drugs in combination with an anti-PD1/PD-L1 agents have failed so far in HNSCC patients. Many other immune-oncology drugs are still in early clinical development and will hopefully improve HNSCC patient outcomes.
ZusammenfassungAktuell entwickeln sich die therapeutischen Möglichkeiten im Gebiet der Kopf-Hals-Onkologie, v. a. durch den Einsatz von Checkpoint-Inhibitoren, rasch weiter. Momentan werden zahlreiche Studien zur medikamentösen Therapie von Kopf-Hals-Karzinomen mit neuen molekularen Targets bzw. neuen Medikamentenkombinationen durchgeführt. Die wichtigsten Ergebnisse der Studien, die bei der ASCO-Jahrestagung 2021 zu Kopf-Hals-Karzinomen vorgestellt wurden, sollen in dieser Arbeit vorgestellt werden.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.